The regulation not only of cellular proteins but also of viral proteins by phosphorylation has attracted research interest for many years. Besides characterization of proteins which become phosphorylated and the identification of their regulatory kinases, much effort has been spent on the analysis of the signaling pathways involved and their functional consequences. We are particularly interested in understanding how the multifunctional nonstructural protein NS1 of the autonomous parvovirus minute virus of mice (MVMp) is regulated. MVM consists of a small icosahedral capsid with a linear singlestranded DNA of negative polarity as a genome. The DNA of MVMp codes for the nonstructural proteins NS1 and NS2, of which the latter exists in three different isoforms, differing in their unique C termini only, as well as two capsid proteins, VP1 and VP2. NS1 is endowed with numerous biochemical activities, such as ATP binding and hydrolysis (12, 62) , helicase (44, 62) , site-specific binding to the cognate recognition motif [ACCA] 2-3 which is scattered throughout the viral genome (13, 19) , and site-and strand-specific endonuclease (11, 18, 44) . Furthermore, NS1 takes part in protein-protein interactions to form homo-oligomers (40, 52) or complexes with cellular partner proteins like the transcription factor SP1 (35) , the cochaperone SGT (20, 58) , or heterogeneous nuclear ribonucleoproteins (28) . NS1 plays a key role in many processes necessary for progeny virus production. Thus, it initiates and regulates viral DNA amplification (for a review, see reference 17) or trans regulates its own P4 promoter (22) as well as the P38 promoter driving capsid gene expression (13, 53) . In addition, NS1 exerts cytotoxic stress on its host cells, which shows itself in cell cycle arrest (49) , disregulation of heterologous promoters (36, 60) , and changes in cell physiology (1) and morphology (9, 14) . Such a diversity of activities implies a tight regulation of NS1 functioning. Indeed, phosphorylation proved to serve as a mechanism for coordination of the various NS1 functions in a time-dependent (15) and subcellular location-dependent (46) manner. Thus, modulations of the NS1 phosphorylation state altered its biochemical profile (43) , and NS1 mutagenesis at consensus (protein kinase C [PKC]) phosphorylation sites selectively impaired the viral polypeptide in some of its functions necessary for virus propagation (14, 21) . Although NS1 comprises more than 100 potential consensus phosphorylation sites and generates more than 20 distinct phosphopeptides when isolated from infected cells (15) , only a few phosphorylated residues of NS1 (14, 21) and a single cellular kinase, namely the atypical PKC (21, 46) , could be identified so far as being involved in the regulation of the viral protein.
The molecular mechanisms of parvoviral DNA replication have been extensively investigated (for a review, see reference 17) . Replication of the single-stranded genome occurs through double-stranded concatemeric DNA intermediates as a result of a rolling circle mode of replication (RCR)-like mechanism similar to the one described for bacteriophages, single-stranded plasmids, and geminiviruses (for a review, see reference 34). Upon entering the nucleus, virion DNA becomes converted into a covalently closed monomeric duplex, which serves as a first transcription template for production of viral proteins, including NS1. In concert with cellular accessory proteins, NS1 generates a free 3Ј hydroxyl group through its site-and strandspecific nicking activity. Thereafter, polymerase ␦ drives the formation of concatemeric duplex intermediates by a unidirectional, leading-strand elongation mechanism. To facilitate strand-displacement synthesis, NS1 works as a processive helicase, unwinding the double-stranded replication template in front of the replication fork. For both the initial nicking reactions at the left-and right-end origins and viral DNA amplification, NS1 physically interacts with cellular components, such as the transcription factor PIF (11) , members of the HMG family (18) , and components of the replication machinery, such as RPA and RF-C (10) .
The regulation of NS1 enzymatic functions in particular during replication of the viral genome has been characterized in detail by using both site-directed mutagenesis (21, 42) and functional in vitro assays in which dephosphorylated inactive NS1 was rescued through incubation with consecutively purified cellular extracts or recombinant protein kinases (43, 45, 46) . Phosphorylation of NS1 residues T435 and S473 by PKC regulates the site-specific binding and DNA unwinding activities of the viral polypeptide. These phosphorylation events also determine the ability of NS1 to site-specifically nick the leftend MVM origin (42) and control strand-displacement synthesis through its processive helicase function (21) . Yet to become fully competent for RCR activity, NS1 requires additional phosphorylation steps executed by an as-yet-undefined TPAresponsive cellular protein kinase (21, 45) .
In this paper we aimed to identify additional kinases that are required for complete activation of NS1 RCR functions. Therefore, the strategy previously described for identification of atypical PKC (45) was applied. Distinct fractions of cellular extracts were tested for their ability to rescue dephosphorylated NS1 in a kinase-free replication system and analyzed for the presence of candidate protein kinases. Finally, fractionation on hydroxyl apatite columns led to the identification of the novel PKC as a prime candidate for the regulation of NS1 RCR functions. The competence for NS1 activation was then confirmed through cloning of the PKC cDNA into a mammalian expression system and testing of the purified recombinant protein in a kinase-free in vitro replication system. Furthermore, the impact of phosphorylation of NS1 by PKC on MVM DNA replication was verified in vivo, using stably transfected cell lines endowed with an altered PKC activity upon infection. Altogether, our results provide strong evidence for the involvement of an additional member of the PKC family, novel PKC, in the regulation of NS1 for viral DNA amplification in cooperation with atypical PKC.
MATERIALS AND METHODS
Antibodies and reagents. Polyclonal antibodies against PKC␤I and PKC␤II, PKC␦, PKCε, PKC, or PKC (C-16, C-18, C-17ϩC-20, E-5, C-15, and N-17) were purchased from Santa Cruz. Monoclonal antibodies recognizing PKC␣, PKC␥, PKC, or PKC were obtained from Transduction Laboratories. The PDK-1-specific sheep polyclonal antibody (06-906) was from Upstate Biotechnology. Horseradish peroxidase-conjugated antirabbit and antimouse antibodies were purchased from Promega, while horseradish peroxidase-conjugated antisheep antibody was obtained from Upstate Biotechnology. Fluorescent dyelabeled secondary antibodies were from Dianova, with the exception of the Cy3-conjugated antirat-antibody purchased from MoBiTec. Rat antibromodeoxyuridine (anti-BrdU) antibodies were obtained from Direct.com.
Cells and viruses. BSC-40, A9 cells, and derivatives thereof were maintained as monolayers in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal calf serum. HeLa-S3 cells were grown in spinner bottles in the presence of 10% fetal calf serum. MVMp was propagated in adherent A9 cells, and virus stocks were prepared by repeated freezing and thawing in 10 mM Tris (pH 8.3)-1 mM EDTA. Recombinant vaccinia viruses were constructed and propagated as previously described (41, 43) . Vaccinia viruses expressing His-tagged NS1 (44) and human (h) or mouse (m) PKCs hPKC␣, hPKC␥, mPKC, and hPKC (21) have been described earlier.
Cloning of PKC cDNAs. Human placenta and A9 cDNA libraries were generated from mRNA preparations using a SMART PCR cDNA synthesis kit (Becton Dickinson, Heidelberg, Germany). PKC was cloned by PCR from the human placenta library in two separate fragments. The N-terminal fragment was obtained using the primer pair A (5Ј-ATGTCGTCTGGCACCATGAAGTTCA ATGGCTATTTGAGGGTCCG-3Ј) and B (5Ј-CCACAGTTAGGGGCCACGT TCGCTTGACATCGAATATGCA-3Ј); for the C-terminal half of the coding region, primers C (5Ј-TGCATATTCGATGTCAAGCGAACGTGGCCCCTAA CTGTGG-3Ј) and D (5Ј-CTATGGTTGCAATTCTGGAGACACATAGGAA AAGTTTCTA-3Ј) were used. The two fragments were then combined through the overlapping sequences of primers B and C by additional PCR and cloned directly into pCR2.1 (Invitrogen). Similarly, mouse PKC␦ and mouse PKCε cDNAs were amplified from the A9 cDNA library. For PKC␦, the following primers were used: A (5Ј-ATGGCACCCTTCCTGCGCATCTCCTTCAATTC CTATGAGC-3Ј), B (5Ј-CCCGGCATTTGTGGTGCACATTCATGCCACAA TCTTCACA-3Ј), C (5Ј-TGTGAAGATTGTGGCATGAATGTGCACCACAA ATGCCGGG-3Ј), and D (5Ј-TTAAATGTCCAGGAATTGCTCAAACTTGG GATTCACAAAG-3Ј). For PKCε we used primers A (5Ј-ATGGTAGTGTTCA ATGGCCTTCTTAAGATCAAAATCTGCG-3Ј), B (5Ј-CTCCGGGGCTTGC CAGCTGGCCATCGGTGGCCGACGACGC-3Ј), C (5Ј-GCGTCGTCGGCC ACCGATGGCCAGCTGGCAAGCCCCGGAG-3Ј), and D (5Ј-TCAGGGCAT CAGGTCTTCACCAAAGTAGGAGAAGCCTTTA-3Ј). All pCR2.1-cDNA clones were sequenced; no differences within the coding sequences were found compared to the GenBank sequences (hPKC, NM_006255; mPKC␦, AB011812; and mPKCε, AF028009).
Plasmid constructs for recombinant PKC expression. (i) Production of purified proteins (see below)
. Plasmid pTMHis, a derivative of pTM-1 which allows the expression of N-terminally His 6 -tagged proteins (45) , was used as an expression vector. To generate the pTHisPKCx plasmids, PCRs were carried out using the above-mentioned PKC clones together with N-and C-terminal primers harboring unique restriction sites compatible with the polylinker in pTMHis1. The N-terminal restriction site was designed to fuse the His 6 tag in frame with the coding sequence of the PKC cDNA. All PCRs were performed according to the manufacturer's recommended conditions using the Advantage HF PCR amplification kit (Becton Dickinson), and products were first subcloned into pCR2.1 (Invitrogen) prior to transfer into the expression vector. The hPKCcoding PCR fragment was generated with the primers 5Ј-TACGGATATCCAT GGCGTCTGGCACCATGAAGTTCAATG-3Ј and 5Ј-TACGTCTAGATATCCT ATGGTTGCAATTCTGGAGACACA-3Ј using pCR2.1-hPKC as a template. This fragment was then cloned as an NcoI-to-EcoRV segment into NcoI-and SmaI-cleaved dephosphorylated pTHis1, giving rise to pTHis hPKC.
The mPKC␦ coding fragment (primers 5Ј-GATATCGAATTCATGGCACC CTTCCTGCGCATCTCCTTCA-3Ј and 5Ј-TCTAGATTAAATGTCCAGGAA TTGCTCAAA-3Ј) was transferred as an EcoRI segment into EcoRI-cleaved, dephosphorylated pTHis1, giving rise to pTHismPKC␦. The mPKCε sequence was transferred as an NcoI-to-XhoI PCR fragment (primers 5Ј-TCAGCCATG GTAGTGTTCAATGGCCTTCTTAAGATC-3Ј and 5Ј-TCAGCTCGAGTCA GGGCATCAGGTCTTCACCAAAGT-3Ј) into similarly digested pTHis1, generating pTHismPKCε.
For PKC expression in stably transfected cells, we used plasmid pP38, obtained by deleting the PmeI-to-PvuII fragment from pdbMVMpdl1200 (33) . This construct drives the expression of foreign genes under control of the parvoviral NS1 protein. For generation of N-terminally Flag-tagged fusion proteins, we used plasmid pP38-Flag, a pP38 derivative that was obtained by inserting the polylinker (5Ј-GCTAATGGCTGACTACAAGGACGACGATGACAAGGCC AAGCTTCGAATTCTGCAGTCGACGGTACCGCGGGCCCGGGAT(X) n G CGGCCGC-3Ј) as an Eco47III and NotI fragment into HpaI-and NotI-digested pP38. The polylinker comprises the Flag epitope (MADYKDDDDKA) and allows the in-frame cloning of foreign sequences through restriction sites for HindIII, EcoRI, SalI, AccI, KpnI, SacII, ApaI, and SmaI. The mutant PKCcDNA clones (see below) were subcloned into pCR2.1 (Invitrogen, Groningen, The Netherlands) prior to transfer into the expression vector pP38-Flag as SmaI-NotI (PKCA160E and T512A) fragments or as a SmaI-to-XbaI (PKC-DN) fragment, respectively. To generate the control pP38GFP plasmid, the coding sequence of enhanced green fluorescent protein (EGFP) (Clontech) was transferred as a StuI-to-XbaI-cleaved PCR fragment (primers 5Ј-AGCTAGGC CTCCATGGTGAGCAAGGGCGAGGAGCTGTTC-3Ј and 5Ј-ATCGCCCGG GTCTAGAGTCGCGGGCCGCTTTAC-3Ј) into HpaI-and XbaI-cleaved pP38.
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(ii) Production of mutant forms of PKC. Site-directed mutagenesis of the hPKC cDNA clone was performed by chimeric PCR using the N-and Cterminal primers 5Ј-CGG GCC CGG GAT ATG TCG TCT GGC ACC ATG AAG-3Ј and 5Ј-GGCGCGCGGCCGCCTATGGTTGCAATTCTGGAGAC-3Ј, together with two overlapping internal primers harboring the mutation. These mutated primers were the following: for PKCA160E (replacing alanine with glutamic acid in the pseudosubstrate region), 5Ј-CAG GAA GCG CCA AAG GGA AAT GCG AAG GCG AGT CCA CC-3Ј and 5Ј-GGA CTC GCC TTC GCA TTT CCC TTT GGC GCT TCC TGG TA-3Ј; and for PKCT512A (replacing the PDK phosphorylation site threonine with alanine), 5Ј-GTC ACC ACG GCC GCA TTC TGT GGC ACG CCA GAC-3Ј and 5Ј-GGC GTG CCA CAG AAT GCG GCC GTG GTG ACA CCA TTG-3Ј (boldface shows mutated residue). Another mutant, PKC-DN, encoding only the regulatory domain of PKC (amino acids [aa] 1 to 296) was generated in a single PCR run using the primer pair 5Ј-CGG GCC CGG GAT ATG TCG TCT GGC ACC ATG AAG-3Ј and 5Ј-TACGTCTAGATATCTTACCCCACAGTTAGGGGCCACGTT-3Ј. Due to primer-related reasons, the C terminus of PKCDN was extended by the following amino acids: RYLELLHMVHFSGKEN. Before transferring into appropriate expression vectors, all three PKC mutants were verified by sequencing.
Protein extraction and fractionation by column chromatography. S100 extracts from HeLa cells were prepared and successively fractionated on phosphocellulose, DE52, and protamine (PA) chloride columns as previously described (45) . The PKC-containing fraction PA-2 was eluted from the column using buffer C (20 mM HEPES [pH 7.5], 1 mM EDTA, 0.1 mM dithiothreitol [DTT], 10% glycerol) containing 1 M NaCl and the protease inhibitors phenylmethylsulfonyl fluoride (174 g/ml), leupeptin (5 g/ml), and aprotinin (2 g/ml). PA-2 was dialyzed, adjusted to 50% glycerol, and stored in aliquots at Ϫ80°C. PKC isoforms present in fraction PA-2 were separated by fast-performance liquid chromatography (Pharmacia) on hydroxyl apatite (HA) columns (Merck). PA-2 (corresponding to a 3-liter culture of ϳ2 ϫ 10 9 cells) was adjusted to 200 mM NaCl, loaded on a 5-ml HA column with constant flux (0.5 ml/min), and washed with 30 ml of buffer C containing 50 mM NaCl. After collection of the flowthrough (HA-0) and wash, the HA-1 fraction (containing the atypical PKC isoforms PKC and PKC) was eluted from the column using buffer D (150 mM NaCl, 20 mM KPO 4 [pH 7.5], 10% glycerol, protease inhibitors phenylmethylsulfonyl fluoride, leupeptin, aprotinin). The bound material (HA-2) comprising the nondefined component(s) necessary for NS1 activation in RCR assays was then further fractionated using a step-gradient of KPO 4 as indicated in Fig. 1 . All fractions were dialyzed against buffer C containing 50 mM NaCl overnight at 4°C, adjusted to 50% glycerol, and frozen in aliquots at Ϫ80°C.
Production and purification of recombinant proteins by means of vaccinia virus expression. NS1 and recombinant PKC isoforms were produced by means of vaccinia virus expression in suspension cultures of HeLa-S3 cells and harvested around 18 h postinfection. His-tagged NS1 present in nuclear extracts was dephosphorylated, or not, with calf intestine alkaline phosphatase and purified immediately on Ni 2ϩ -nitrilotriacetic acid agarose columns (43) . The protein preparations were analyzed by discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and detected either by Coomassie blue staining (staining buffer: 25% methanol, 10% acetic acid, 0.1% Coomassie brilliant blue; destaining buffer: 25% methanol, 10% acetic acid) or by Western blotting.
In vitro replication assays. Template plasmids pL1-2TC and pL1-2GAA containing the minimal active left-end MVM origin and the corresponding inactive origin, respectively, were described and characterized previously (16) .
Replication assays were carried out as described previously (45) in the presence of optimized P1-Thr subcellular fractions, 3 U of T4 DNA polymerase, and approximately 200 ng of His-tagged vaccinia virus-produced NS1 (as determined by Coomassie blue staining after SDS-PAGE). P1-Thr consists of the flowthrough fraction of 293 cell extracts purified on phosphocellulose columns and relieved of endogenous serine-threonine kinases by L-Thr-affinity chromatography. This fraction contains the replication factors RPA, PCNA, and PIF. The assays were carried out in a 20-l total volume of 20 mM HEPES-KOH (pH 7.5), 5 mM MgCl 2 , 5 mM KCl, 1 mM DTT, 0.05 mM (each) deoxynucleoside triphosphates; 2 mM ATP, 40 mM creatine phosphate, 1 g of phosphocreatine kinase, 10 Ci of [␣-
32 P]dATP (3,000 mCi/mmol), and 20 ng of the appropriate DNA template (pL1-2TC or pL1-2GAA). After incubation at 37°C for 2 h, the reaction was stopped by adding 60 l of 20 mM Tris (pH 7.5)-10 mM EDTA-0.2% SDS and heating the mixture to 70°C for at least 30 min. The reaction products were analyzed by agarose gel electrophoresis after immunoprecipitation with anti-NS N antiserum and digestion with HindIII.
In vitro kinase reactions. In vitro kinase reactions were performed as described previously (43) . Dephosphorylated NS1 O (200 ng) was incubated with purified recombinant PKC or PKC (100 ng) in the presence of 20 mM HEPES-KOH (pH 7.5), 7 mM MgCl 2 , 5 mM KCl, 1 mM DTT, 10 Ci of [␥-
32 P]ATP (3 Ci/mmol) and PKC cofactors (1 g of L-␣-phosphatidyl-L-serine/ ml, 1 nM TPA). After incubation for 30 min at 37°C, the reactions were stopped by adding the same volume of 20 mM Tris (pH 7.5)-5 mM EDTA-0.2% SDS, and heating for 30 min at 70°C. The reaction products were immunoprecipitated with anti-NS N antiserum and analyzed by SDS-10% PAGE and autoradiography after blotting on nitrocellulose or polyvinylidene difluoride membranes.
Generation of stably transfected A9 cell lines. Stable transfectants were generated by cotransfection of 10 5 A9 cells with 25 g of the appropriate pP38-X construct together with pSV2neo, in a molar ratio of 25:1, using 25 l of Lipofectamine (Invitrogen) according to the manufacturer's protocol. Two days posttransfection, cultures were split 1:10, and transfected cells were selected using 400 g of G418 (Sigma)/ml. Colonies were pooled after growth for approximately 4 weeks under selection, and frozen stocks were prepared. All experiments were performed after additional cell growth for several passages in the absence of selection in order to avoid physiological side effects of G418. To obtain optimal reproducibility, all transfectants were kept in culture for limited times only (fewer than 25 passages).
Western blotting analyses. Protein extracts were separated by discontinuous SDS-10% PAGE and blotted onto nitrocellulose membranes. Proteins of interest were detected by incubation with appropriate primary antibodies in 10% dry milk-phosphate-buffered saline (PBS) for 18 h and staining with horseradish peroxidase-conjugated secondary antibodies for 1 h followed by chemiluminescence detection (Amersham).
Immunofluorescence microscopy. For examination by immunofluorescence microscopy, cells were grown on spot slides, mock or MVMp infected, and further incubated for appropriate times. Cultures were fixed using 3% paraformaldehyde in PBS (pH 7.4) for 30 min at room temperature, neutralized with 50 mM NH 4 Cl in PBS for 6 min, and permeabilized by treatment with PBS containing 0.1% Triton X-100 for 10 min. All solutions were supplemented with 1 mM MgCl 2 and 0.5 mM CaCl 2 . After extensive washing, cells were blocked with 10% goat serum for 30 min, incubated with primary antibodies for 2 h at room FIG. 1. Purification of NS1-regulating kinases from crude HeLa cell extracts. Protein kinases regulating NS1 for replicative functions were purified on phosphocellulose, DE52, protamine chloride, and HA columns as described previously (45) . To identify the NS1 O -activating protein kinases, the protamine-bound components were fractionated by HA chromatography, using a step gradient, increasing KPO 4 concentrations as indicated. Atypical PKC/, necessary to activate NS1 O for DNA unwinding activities, eluted at 20 mM KPO 4 (HA-1 fraction). Besides HA-1, the HA-2 fraction was required to fully activate NS1 for RCR. To further separate protein kinases with higher affinity to HA (HA-2 fraction), elution was carried out at higher KPO 4 concentrations, yielding subfractions A to E. temperature, and last, incubated with fluorescein isothiocyanate (FITC)-or CY3-conjugated anti-species specific antibodies (Dianova) for detection purposes. After mounting using Elvanol, cells were analyzed by conventional epifluorescence microscopy (ϫ63 lens with immersion oil; Leica) or confocal laser scanning microscopy (Leica TCS SP laser fitted to a Leica IMRBE microscope).
NS1 metabolic labeling, purification, and phosphopeptide analyses. Metabolic labeling of NS1 and tryptic phosphopeptide analyses were essentially performed as previously described (43) 7.4] , 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Na-deoxycholate, 1% Triton X-100) containing protease and phosphatase inhibitors. NS1 immunoprecipitations were carried out using 10 l of anti-NS N antiserum for 2 h at room temperature. Immune complexes were precipitated with protein A-Sepharose, washed with RIPA buffer, and further purified by SDS-10% PAGE.
32 P-labeled proteins were revealed by autoradiography after blotting on polyvinylidene fluoride membranes, and the band corresponding to NS1 was excised. Digestion of membrane-bound NS1 was performed with 50 U of trypsin for 18 h at 37°C. Tryptic peptides contained in the supernatant were recovered by lyophilization and analyzed on thin-layer cellulose plates (Merck) in two dimensions, first by electrophoresis using a pH 1.9 buffer and then by chromatography in phospho-chromatography buffer.
MVM DNA replication in infected cells. The accumulation of MVM DNA replicative forms was analyzed by Southern blotting as described by Corbau et al. (15) . A9 cells (or derivatives A9:P38-PKCA160E, A9:P38-PKCT512A and A9:P38-PKCDN) (3 ϫ 10 5 ) were infected with MVMp (10 PFU/cell). Cells were harvested after 2, 24, 48, and 72 h postinfection in TE (10 mM Tris-HCl [pH 8.0], 1 mM EDTA) and digested with proteinase K in 0.1% SDS for 18 h at 46°C. The whole-cellular DNA was then sheared by passage through a syringe, fractioned by 0.8% agarose gel electrophoreses, and blotted on a nitrocellulose membrane. Viral replicative intermediates were then detected using a 32 P-labeled probe corresponding to nucleotides 385 to 1885 of the NS1-coding region of MVMp.
For in situ viral DNA replication studies, cells were grown on coverslips and infected with MVMp (50 PFU/cell) for 24 or 48 h. At various times, cells were labeled with 10 M BrdU in DMEM for 25 min at 37°C and fixed with 3% paraformaldehyde. Replicating viral DNA was detected by immunofluorescence as described above using a monoclonal rat anti-BrdU antibody and quantitatively analyzed.
RESULTS
The novel isoform PKC activates NS1 in cooperation with PKC for RCR. Previous investigations have identified atypical PKC phosphorylation to be essential to activate NS1 for initiation of viral DNA amplification. This phosphorylation event proved sufficient to activate the viral polypeptide for DNA unwinding during the initial nicking reaction and the processive helicase function in front of the replication fork (21, 42, 46) . However, PKC phosphorylation alone did not enable dephosphorylated NS1
O to drive RCR in concert with the cellular replication machinery (21, 45) . Additional cellular factor(s) appear to be necessary, which due to their cofactor requirements (45) are also likely to belong to the PKC family. To identify such components involved in phosphorylation and activation of NS1 for RCR, we used a previously established complementation approach based on a kinase-free in vitro replication system (45) . Circular plasmids containing the leftend origin of MVM DNA replication were subjected to RCR reactions in the presence of NS1 O , recombinant PKC, and PKC-activating cofactors. In addition, the system was complemented with distinct fractions from HeLa cell extracts. Figure  1 depicts our purification strategy for identification of protein kinases, which activate NS1 for RCR in the presence of PKC. As previously described (45) , the component(s) required to activate NS1 O for RCR besides PKC copurified with PKC through phosphocellulose, strong anion exchange, and protamine affinity chromatography but could be separated from PKC due to their higher affinity to HA. Atypical PKCs, including PKC/, were eluted from HA columns with as little as 20 mM KPO 4 in the so-called HA-1 low-affinity fraction. The bound material constituting the high-affinity HA-2 fractions was previously shown to comprise a factor(s) complementing PKC (or HA-1) for NS1 activation in a TPA-dependent fashion (45) . To characterize this factor(s), the HA-2 fraction was further purified by step-gradient elution. Five subfractions (A to E) eluting at 116, 164, 212, 260, and 500 mM KPO 4 , respectively, were collected. Interestingly, a significant accumulation of proteins in the range of 70 to 90 kDa was observed, particularly in fractions with higher HA affinity ( Fig. 2A) . This size, together with the previously reported cofactor requirements of Figure 2B illustrates the distribution of individual PKC isoforms separating on HA. PKC␣, PKC␥, and PKCε could not be detected in any HA fraction, since they became lost during previous chromatography steps. In contrast, PKC␤I/II, PKC␦, PKC, and PKC as well as the PKC activator kinase PDK-1 were retained on HA due to their distinct affinity to the matrixes used in the purification procedure. The consecutive elution of the HA-bound protein kinases with increasing amounts of KPO 4 revealed the PKC isoforms PKC␤I/ II, PKC␦, PKC, and PDK-1 to be recovered at relatively low concentrations, with the greater part of each of these proteins being present in subfraction HA-2A. Interestingly, although peak amounts of these kinases were indeed released in HA-2, a significant proportion was still present in HA-1 (Fig. 2B , lane 2), hence excluding PKC␤I/II, PKC␦, PKC, and PDK-1 as coactivators for atypical PKC (21, 45) . In contrast, the novel PKC was retained on the HA matrix during the first elution steps, coming off the column at a rather high KPO 4 concentration in subfraction C, with only a minor proportion being present in subfraction HA-2B. The HA-2 subfractions were then tested for their capacity to activate dephosphorylated NS1 O for RCR initiation in a kinase-free in vitro replication system. This in vitro assay is based on a Thr-affinity-purified subcellular fraction containing RPA, PCNA, the parvovirus initiation factor PIF, and bacteriophage T4 DNA polymerase. To search for the additional NS1-activating factors present in HA-2 (subfractions), we supplemented the replication reactions with the PKC cofactors PS and TPA as well as recombinant PKC to activate NS1 DNA unwinding functions (21, 42) . All replication reactions were performed at 37°C for 2 h in the presence of [␣-
32 P]dATP. DNA was then immunoprecipitated with anti-NS N and analyzed by 0.8% agarose gel electrophoresis in order to discriminate between random nick-translation activity and genuine NS1-initiated replication products. As illustrated in Fig. 3 (lanes 3 to 9), no detectable RCR activity was obtained with dephosphorylated NS1
O in the absence of PKC and, as expected from previously published results (21, 46) , only a marginal stimulation was observed upon addition of recombinant PKC alone (lane 5). In contrast, further supplementation of the assay with distinct HA-2 subfractions eluting at high KPO 4 concentrations resulted in a significant rescue of NS1 O replication activity. Maximum rescue was achieved with fraction HA-2C, which cooperated with PKC to activate NS1 O up to a 10-fold-higher level than PKC alone (Fig. 3, lane 7) . Reactivation of NS1 O dropped significantly towards both ends, elution with higher and lower KPO 4 concentrations, being only 5-and 2-fold for HA-2D and HA-2B, respectively (Fig. 3 , lanes 6 and 8) and getting undetectable for HA-2A (data not shown). This distribution allowed us to draw a parallel between the NS1 activation potential of the different HA-2 subfractions and their respective contents in PKC as measured by Western blotting. Among the kinases detected within the HA-2 components, only PKC was found to concentrate in the most active HA-2C subfraction (compare Fig. 2B and 3) . In contrast, the elution of PKC␤I/II, PKC, or PKC␦ peaking in HA-2A did not match the activation profile, while PKC␣, PKC␥, and PKCε were already excluded as candidate coactivators from prior purification steps. Thus, this correlation strongly argued for an involvement of the novel PKC isoform in the activation of NS1 for RCR activity.
In order to determine whether PKC is indeed able to activate NS1 for RCR, we carried out the in vitro replication reaction in the presence of recombinant PKC and PKC without the additional components present within the HA-2 subfractions. To produce recombinant PKC, we isolated a full-length cDNA clone from a human placenta cDNA library, cloned it into plasmid pTHis1, and generated recombinant vaccinia viruses. Expression of PKC was driven under control of bacteriophage T7 polymerase and an encephalomyocarditis virus leader sequence for cap-independent high efficiency translation in the presence of a second recombinant vaccinia   FIG. 3 . Reactivation of dephosphorylated NS1 in in vitro replication assays. NS1-dependent RCR of plasmids containing the left-end active (T) or inactive (G) origin was determined in a kinase-free in vitro system based on P1-Thr and T4 DNA polymerase (45) . The reaction products were analyzed by 0.8% agarose gel electrophoresis after immunoprecipitation with anti-NS N antiserum, HindIII restriction digestion, and deproteination. The migration of the linearized plasmid is indicated with an arrow. Lanes 1 and 2, fully phosphorylated NS1; lanes 4 to 17, dephosphorylated NS1 O using alkaline phosphatase; lanes 5 to 9 and 12 to 17, reactions performed in the presence of indicated HA-2 subfractions (B, C, and D) and/or recombinant activated PKCs (, , ␦, and ε).
virus, vTF7-3, to provide the T7 RNA polymerase. The recombinant protein was produced in HeLa cells and purified by means of its N-terminal His 6 tag on Ni 2ϩ -nitrilotriacetic acid agarose columns. For comparison, we also generated recombinant vaccinia viruses expressing the novel PKC␦ and PKCε, since these closely related kinases might be substituted for PKC under in vitro conditions when applied at high concentrations. The impact of these PKCs on NS1 regulation was then tested in in vitro replication assays as described above, replacing the HA-2 subfractions with the different recombinant PKC isoforms. As shown in Fig. 3 (lanes 10 to 17) , recombinant PKC was indeed able to stimulate the NS1 O replication activity more than 10-fold in the presence of PKC, while PKC alone was inefficient (lane 13). PKCε (lane 16) had only a marginal effect, stimulating NS1 O by two-to threefold in comparison with PKC alone. Interestingly, recombinant PKC␦ expressed in mammalian cells was able to substitute for PKC in NS1
O rescue, but with a significantly lesser efficiency (ϳfive-fold increase of activation achieved by PKC alone), in keeping with the somewhat relaxed phosphorylation specificity of PKCs under in vitro conditions (38) . No activation was obtained by complementing PKC with recombinant conventional PKCs (PKC␣, PKC␥, and PKC␤I/II) or PKC␦ expressed in insect cells from recombinant baculoviruses (data not shown). In summary, although high amounts of purified recombinant PKC␦ were able to stimulate to some extent the in vitro replication activity of NS1 O in the presence of PKC, our results obtained with fractionated cell extracts and recombinant PKCs provide strong evidence to suggest that PKC is a prime candidate for the regulation of NS1 replicative functions in cooperation with PKC.
Production of A9 cell-derived stable transfectants harboring MVM-inducible PKC mutant clones. In order to assess a possible role of PKC during MVM infection, we chose to modulate PKC activity in A9 cells through the expression of mutant forms of the enzyme. For this purpose, we stably transfected A9 cell lines with PKC mutant clones under control of the NS1-inducible P38 promoter. The generation of such stable transfectants offers several advantages. (i) As determined with a P38-driven EGFP construct (pP38-GFP), more than 95% of stably transfected cells were able to produce the foreign polypeptide upon infection, with no need to use other inducers that may perturb the system (data not shown). (ii) Due to integration into the chromosomal background, expression levels remained in a physiological range even upon induction for the majority of cells. Quite often a controlled expression of a foreign sequence can be problematic by episomal expression in transient-transfection assays (see below). (iii) Since the P38 promoter is induced through the viral protein NS1, elevated expression of the transgene should be reached after establishment of the MVM infection and, therefore, should have little impact on receptor interaction or virus entry. (iv) The introduction into the chromosomal background and steady-state expression of the transgene do not affect viability and propagation of the cell population, since they have to be maintained over an extended time period during the selection procedure.
As illustrated in Fig. 4 , the following PKC mutants were constructed to alter endogenous PKC activity. By mutagenesis of the pseudosubstrate domain at amino acid position 160 from alanine to glutamic acid, we generated the constitutively active variant PKCA160E. It has been demonstrated for other PKC isoenzymes (4; J. P. F. Nüesch, unpublished data) that similar mutations at this site render PKC isoforms' activity independent of cofactors such as phosphatidylserine, diacylglycerol, or TPA due to reduced intramolecular binding of the regulatory domain to the substrate recognition site in the catalytic pocket. In contrast, substitution of alanine for threonine at T512, a PDK-phosphorylation site within the activation loop, results in a catalytically inactive mutant (PKCT512A). Indeed, this PKC variant does not undergo the phosphorylation-dependent conformational changes required for its functioning, since the T512A substitution prevents the kinase from all (auto)phosphorylations at its C terminus (23; Nüesch, unpublished data). Overexpression of the mutant form PKCT512A is expected to inhibit endogenous PKC activity due to substrate competition. In addition, we constructed a dominant-negative mutant, PKCDN, consisting of the isolated regulatory domain. As previously established for PKC (46) , overexpression of the regulatory domain (aa 1 to 296) inhibits endogenous active PKC. It is thought that this polypeptide, PKCDN, which harbors the pseudosubstrate site, blocks the substrate recognition motif of PKC with high specificity and affinity. Since this artificially expressed regulatory domain is not connected to the kinase, conformational alterations induced by cofactor interactions are not able to release this block of the active site (39) . All three mutants were constructed with an N-terminal Flag epitope, cloned into the expression plasmid pP38 and stably transfected into the mouse fibroblast cell line A9, in the presence of a neomycin resistance plasmid, pSV2neo. The isolated stable transfectants were first analyzed by confocal immunofluorescence microscopy to determine expression and subcellular localization of the recombinant proteins , and fixed at 44 h p.i. Endogenous PKC was detected with a polyclonal rabbit antiserum and CY3-labeled anti-rabbit secondary antibodies, while the mutant PKC proteins were visualized with a mouse monoclonal Flag antibody and CY3-conjugated anti-mouse secondary antibody. NS1 was revealed using either a monoclonal mouse antibody and FITC-conjugated secondary anti-mouse antibodies or polyclonal rabbit antiserum and FITC-labeled anti-rabbit antibodies. All images were acquired using a Leica TCS SP Microscope (ϫ63 oil immersion lens, FITC/tetramethyl rhodamine isocyanate filter settings, and a pinhole of 1). Cells were stained for endogenous PKC (panels 1 A and B), recombinant PKC (panels 2A and B to 4A and B), or NS1 (panels 1 to 4C); panel D, merged images.
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cytoplasmic but showed a clear perinuclear accumulation in the majority (50 to 60%) of NS1-expressing cells (panels 1B to 1D). According to the current model of PKC activation cascades, this redistribution could indicate activation of the kinase as a result of MVM infection (39) . Recombinant PKC variants could be detected independently of the endogenous protein due to their N-terminal Flag epitope (Fig. 5, lanes 2 to 4) . As expected from previous analyses using episomal (53) or stably integrated P38 promoter constructs (41), expression of the PKC variants was stimulated upon MVM infection in our stable cell lines, though to an extent which varied within the cell population (rows B and D versus row A). These variations are most likely due to the fact that pooled, rather than cloned, transfectants were used in our experiments, resulting in heterogeneous transgene integration patterns. The recombinant full-length PKC variants showed a uniform cytoplasmic distribution similar to that of the endogenous polypeptide. Some unique features of this distribution are worth mentioning. Although the majority of the population expressed the transgene at levels close to the detection limit, approximately 10% of the cells showed strong accumulation of the PKC variants upon MVM infection. Within these overexpressing cells, the constitutively active PKCA160E and the catalytically inactive PKCT512A were both found to have a cytoplasmic localization (Fig. 4, lanes 2 and 3) , suggesting that PKC regulation may not involve the nuclear translocation as previously reported for classical PKCs (39) . The expression level of the N-terminal part of PKC (the dominant-negative PKCDN) was very low even upon induction by MVM NS1 (Fig. 5 , panels 4B to 4D), with the exception of a few strongly overexpressing cells, as shown in Fig. 5 (panel 4B) . In contrast to the full-length enzymes, this polypeptide was found in the cytoplasm, nucleus, or vicinity of the nuclear membrane, probably as a result of its relatively small size (Ͻ40 kDa). Altogether, these data showed that the recombinant PKC variants were indeed expressed upon infection with MVM and constituted a suitable tool to be tested for their effects on virus replication.
The production of all recombinant proteins was also confirmed through Western blotting and in vitro transcriptiontranslation experiments. A rather high basal level of expression of PKCA160E and PKCT512A under control of the P38 promoter was detected even under noninduced conditions. However, this expression level was significantly increased (between twofold [for PKCT512A] and fivefold [for PKCA160E]) upon MVM infection (data not shown). In addition, it should be stated here that the cell populations harboring either one of the three PKC constructs were competent for MVMp entry and expression of NS1 proteins (Fig. 5,  row C ). Yet the efficiency of virus uptake, as measured by the presence of single-stranded DNA (Southern blot) or capsids (immunofluorescence) at different time points postinfection (p.i.), was significantly impaired under PKC knock-down conditions. Indeed, it appeared that the virus uptake was delayed for several hours in the presence of PKCDN or ⌻512A (data not shown). Despite these side effects, the cell lines expressing PKC variants are still valuable tools for studying the impact of PKC on MVM DNA replication in vivo.
NS1 phosphorylation by PKC in vitro and in vivo. The above-mentioned activation of dephosphorylated NS1 O for replication activity in vitro by recombinant PKC provides strong evidence to suggest that NS1 constitutes a direct substrate for phosphorylation and regulation by PKC. To further study the NS1 PKC interplay, we investigated whether PKC is indeed able to phosphorylate NS1 in vitro, and if so, whether NS1 is a substrate for this protein kinase in vivo as well. In vitro phosphorylation of dephosphorylated NS1 O was first tested in the presence of the PKC activators PS and TPA, [␥-32 P]ATP, and recombinant PKC. As a positive control the assay was also carried out using recombinant PKC, also derived from vaccinia virus expression in HeLa cells, for which NS1
O is known to be a target in vitro (21) . The 32 P-labeled NS1 protein was then immunoprecipitated with anti-NS1 H and analyzed by SDS-PAGE. Although the extent of phosphorylation achieved by PKC was significantly less than that with PKC, NS1 O proved to be a target substrate for PKC in vitro (Fig. 6A,  lanes 1 to 3) . This result shows that NS1 indeed serves as a direct substrate for PKC phosphorylation in vitro. Therefore, this kinase might also act as a direct regulator of NS1-driven replication in vivo, as suggested by the PKC-mediated activation of NS1
O for RCR in in vitro assays. To determine whether PKC also contributes to NS1 phosphorylation in the cellular environment, we performed metabolic 32 P labeling and tryptic phosphopeptide mapping of purified NS1 proteins after MVM infection. To inhibit the endogenous PKC activity, we used the P38-PKCDN cell line and compared the phosphorylation pattern of NS1 in these cells and the parental A9s during the replicative phase of an MVM infection. Subconfluent A9 or A9:P38-PKCDN cells were infected with 30 PFU of MVMp/cell for 20 h and metabolically 32 P labeled for an additional 4 h. Cells were harvested directly into lysis buffer 24 h postinfection, and NS1 was isolated by immunoprecipitation using anti-NS1 N antiserum and further purified by SDS-PAGE. The NS1-associated phospholabeling was much reduced in the presence of PKCDN (data not shown). This overall effect could be caused by impairment of NS1 phosphorylation and/or production. In order to distinguish these two possibilities and to determine whether specific NS1 residues were indeed targeted by PKC, we performed two-dimensional tryptic phosphopeptide analyses. The loss or reduction of a distinct NS1 phosphopeptide(s) under PKC knock-down conditions should indeed provide direct evidence of the involvement of PKC in NS1 phosphorylation. As previously reported (15, 43) and illustrated in Fig. 6B (a and b) , NS1 from MVM-infected A9 cells (panel b) showed a characteristic tryptic phosphopeptide pattern after two-dimensional thin-layer electrophoresis-chromatography. This overall pattern of NS1, including the characteristic PKC phosphopeptides, could still be recognized under conditions where endogenous PKC was inhibited by the presence of PKCDN. However, in contrast to the A9-derived phosphopeptide pattern, three distinct phosphopeptides (Fig. 6B, panel c, arrows) were markedly underrepresented. This selective inhibition of distinct phosphorylation events in the presence of PKCDN argues for the contribution of PKC in the phosphorylation of NS1 in A9 cells. Moreover, the involvement of PKC in the phosphorylation of NS1 in vivo is in agreement with the proposed role of this cellular kinase for the regulation of NS1 functioning.
Impact of PKC phosphorylation of NS1 on MVM DNA replication. The results described above using the kinase-free in vitro replication system indicate that PKC phosphorylation is essential to enable NS1 O (in concert with PKC) to drive viral DNA amplification at least in vitro. To ascertain whether phosphorylation of NS1 by PKC was indeed of functional relevance in vivo, we set out to analyze MVM DNA replication in the presence of the PKC variants, i.e., under conditions modulating the intracellular PKC activity. For this purpose the previously described stably transfected A9 derivatives (A9: P38-PKCA160E, A9:P38-PKCT512A, and A9:P38-PKCDN) were used and analyzed for their competence in viral DNA amplification in comparison with the parental A9 cells in timecourse experiments. As illustrated in Fig. 7 (upper panel, lanes 1  to 10) , the parental A9 cell line and A9:P38-PKCA160E (overexpressing the constitutively active PKC mutant form) were both able to support the production of viral DNA replicative intermediates (monomeric and dimeric RF) as well as progeny single-strand virion DNA to similar amounts at all time points. In contrast, A9:P38-PKCT512A and A9:P38-PKCDN cells were both impaired to support viral DNA amplification. In fact, even as late as 72 h postinfection (lanes 11 to 20), viral replication intermediates were barely detectable under these conditions. Thus, inhibiting endogenous PKC activity resulted in a marked sup- pression of the cell capacity for MVM DNA replication. Although delayed virus entry was observed for these PKC cell lines, it cannot account for the dramatic effect on viral DNA amplification observed with A9:P38-PKCDN and A9:P38-PKCT512A, particularly since the amount of replicative forms does not increase even as late as 72 h p.i. In addition, the poor viral DNA amplification in the presence of PKCDN or PKCT512A also caused a striking reduction in the production of viral proteins, as shown for NS1, presumably due to limiting amounts of transcription templates (Fig. 7, lower panel) . Such loop-back regulation could certainly contribute significantly to the dramatic negative effect observed on the replication activity under these conditions. To rule out that catalytic inactive PKC mutants decreased the overall viral DNA amplification merely due to a reduced fraction of cells that became infected, MVM DNA replication was also measured on the single-cell level. For this purpose, A9, A9:P38-PKCA160E, A9:P38-PKCT512A, or A9:P38-PKCDN cells were seeded on coverslips and infected with MVMp (multiplicity of infection, 50). Either 24 or 48 h postinfection, the culture medium was replaced with 10% DMEM containing 100 nM BrdU to allow incorporation of the nucleotide for 25 min into replicating DNA. To determine the rate of viral DNA replication, cells were fixed with 3% p-formaldehyde and subjected to double-immunofluorescence analysis using monoclonal rat anti-BrdU and polyclonal rabbit anti-NS1 antiserum. In the absence of HCl treatment, incorporation of BrdU into replicating chromosomal DNA cannot be detected (2, 61) . This allowed the generation of parvoviral replicative forms during the labeling period to be revealed by anti-BrdU immunostaining. Only NS1-positive cells were analyzed for the extent of BrdU incorporation, to rule out side effects of the PCK knock-down prior to the establishment of a productive infection. Since the intensity of BrdU staining varied significantly between individual cells in an infected population, we decided to distinguish between weak (punctate) and strong (full-blown) BrdU signals. The results obtained 24 and 48 h p.i. are summarized in Fig. 8 . As expected from our analyses of the whole-cell population by Southern blotting, the cell lines with reduced PKC activity could be distinguished from the parental and constitutively active A9:P38-PKCA160E cell line by a striking reduction of the fraction of NS1-positive cells that also scored positive for strong BrdU incorporation. Inactivation of PKC in the A9:P38-PKCT512A and A9:P38-PKCDN cell lines did not allow virus replication to recover at later time points. On the contrary, the fraction of NS1-positive cells with strong BrdU signals dropped further with time. Since only NS1-positive cells, i.e., cells that were able to establish a productive infection, were taken into account, these results confirm that conditions inhibiting the endogenous PKC activity also impaired the capacity of cells to support viral DNA amplification, irrespective of their competence of viral uptake. Together with the Southern blotting and in vivo phosphorylation analyses, these data strongly support the functional role of PKC in the regulation of NS1 during viral DNA amplification.
DISCUSSION
Previous investigations have shown that MVM DNA amplification is tightly controlled by phosphorylation of the initiator protein NS1 (43, 45 (42, 46) . The data presented here identify an additional member of the PKC family, the novel isoform PKC, which is able to phosphorylate and regulate the large nonstructural protein NS1 of MVMp. We show that PKC activates NS1 in cooperation with PKC for RCR in vitro. This in vitro activation appears to be specific for PKC, since other members of the PKC family, such as the conventional PKC␣, PKC␤I/␤II, and PKC␥ or the novel PKCε, failed to activate NS1, despite their ability to phosphorylate the viral polypeptide (21) . To study the impact of PKC on viral DNA replication in vivo, we produced stably transfected cell lines whose overall PKC activity was altered due to the expression of mutant forms of this kinase. Inhibition of endogenous PKC activity upon MVM infection led to a drastic reduction in the accumulation of viral DNA replication intermediates as measured in the whole-cell population as well as on the level of the single cell. Together with the observed alterations of the NS1 phosphorylation pattern in the presence of a dominant-negative PKC mutant, these results underline the importance of PKC for the regulation of a productive MVM infection in permissive cells.
The mechanism by which PKC controls NS1-driven MVM DNA amplification remains to be elucidated. Unwinding and nicking of the left-end origin under physiological conditions could be reconstituted in vitro using dephosphorylated NS1 and activated purified recombinant PKC (42) . This finding demonstrates that PKC is dispensable for the activity of a number of NS1 functions, such as ATP binding and hydrolysis, oligomerization, site-specific interaction with the cognate DNA motif, cleavage of the single-stranded nicking motif, trans esterification with the free 5Ј end of nicked DNA, and the interaction with the cellular cofactor PIF. Furthermore, the processive helicase function of NS1, which is thought to act in front of the replication fork to promote strand-displacement synthesis achieved by polymerase ␦, is independent of PKC phosphorylation (21) . This leads us to speculate that PKC may regulate the interaction of NS1 with the cellular DNA replication machinery, coupling the opening of duplex viral DNA intermediates with leading strand synthesis. NS1 has recently been shown to interact with various components of the replication complex, including the single-strand binding protein RPA and the accessory protein complex RF-C (10). Altogether, these and the present observations raise the intriguing possibility that the interaction of NS1 with one and/or another of these factors (including the active polymerase) might be regulated by PKC phosphorylation of the viral products. Indeed, phosphorylation can control protein-protein interactions, since the transfer of a negative charge to the protein is often accompanied with a change in the conformation of the polypeptide and, in consequence, its affinity towards distinct partner proteins (38) . Identification of the target PKC phosphorylation sites in NS1, assignment of these sites to functional domains, and molecular analyses of the corresponding NS1 mutants should help to further characterize the NS1 feature(s), which is (are) regulated through PKC.
Although inhibition of endogenous PKC mainly affected viral DNA amplification, virus uptake was also impaired to a significant extent in the presence of kinase-inactive PKC mutants. In contrast, the cell line expressing the constitutively active mutant PKCA160E was fully proficient in this process. The mechanism by which PKC may regulate virus entry is currently a matter of speculation, especially since the MVM receptor remains to be identified. It is noteworthy, however, that there are precedents for an impact of PKCs on receptoractivated processes. Indeed, PKC activity was found to correlate with the amount of the retinoic acid receptor protein (8) , to affect internalization of some receptors (6) including the serotonin receptor 5-HT2A (7), to regulate the intracellular trafficking of the insulin growth factor receptor II (29) , or to promote receptor recycling (5, 57) . In contrast, the transferrin receptor, which has been identified as the receptor for the canine parvovirus (51) , was shown to be downregulated upon prolonged PKC activation by phorbol esters (55) . Altogether, considering these observations, it seems conceivable that under reduced PKC activity (as achieved in the presence of the inactive PKC mutants) the MVM receptor might become a limiting factor, due either to its amount or to its ability to guide the intracellular trafficking of the input virus.
The propagation of autonomous parvoviruses is highly dependent upon the proliferation and differentiation state of host cells. These restrictions are likely to account for the preferential multiplication of these agents in a number of neoplastically transformed cells, a property designated oncotropism (for a review, see reference 54). Given their disregulation in many transformed cells, protein kinases, particularly PKCs, are intriguing candidates for oncotropic determinants to stimulate parvovirus propagation in these cells. It is worth noting in this respect that in contrast to the ubiquitous PKC, PKC is expressed in a tissue-specific fashion. The modulation of PKC by differentiation can be exemplified by predominant expression in cells of epithelial origin (3, 26, 50) and in neuronal precursors (24, 47) . Furthermore, like other PKC isoforms, PKC is activated in the presence of tumor promoters, such as TPA. It is therefore possible that neoplastic transformation of certain tissues may result in activation of PKC, which contributes to their enhanced permissiveness for parvovirus infection. This putative role of PKC in cell tropism of parvoviruses remains, however, to be tested experimentally.
PKC family members often undergo intracellular translocation upon activation, becoming increasingly bound to insoluble membranes as demonstrated by immunofluorescence and biochemical analyses (39) . In unstimulated endothelial cells, for instance, PKC was found predominantly in the perinuclear region or at the Golgi apparatus, while induction through TPA led to the translocation of a significant proportion of these enzymes towards the nuclear membrane and into the nucleus (27) . Our immunofluorescence analyses of A9 fibroblast cells showed a similar redistribution of endogenous PKC upon MVM infection, although PKC was unable to enter the nucleus even as a constitutively active variant. In summary, despite the fact that our observations need additional investigations, the translocation of endogenous PKC upon MVM infection provides the first evidence to suggest that viral infection is indeed accompanied by activation of this kinase in A9 cells.
As a result of their subcellular redistribution and activation (48) and their interaction with distinct cofactors or partner proteins (30) , PKC isoforms are able to induce a wide spectrum of signaling cascades (56, 59) . This makes it possible that a single PKC isoform is able to take part in multiple (and even antagonistic) signaling events, depending on the cell type and/or the trigger event involved. The redistribution of PKC induced by MVM is likely to give rise to a positive feedback loop, causing the activated enzyme to stimulate MVM DNA replication through NS1 modification. In addition, however, the activated kinase may also conceivably serve different functions advantageous for the virus life cycle. Stimulation of PKC isoenzymes, (including the novel PKC and PKC␦) have indeed been shown to have a strong impact on cell physiology, influencing more particularly cell cycle progression (25, 37) , differentiation, and transformation (31, 32) . In agreement with the observed morphological alterations imposed on the host cell upon infection and overexpression of PKC, this interplay with the PKC signaling pathway could ensure a suitable environment for virus propagation after infection of target cells.
